Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities of the Company.

Neither this announcement nor any copy thereof may be released into or distributed directly or indirectly in the United States or any other jurisdiction where such release or distribution might be unlawful.

This announcement does not constitute or form a part of any offer or solicitation of an offer to purchase or subscribe for securities in the United States. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any other applicable securities laws of the United States, and may not be offered, sold or otherwise transferred in the United States unless registered under the U.S. Securities Act or pursuant to an exemption from, or in a transaction not subject to, registration under the U.S. Securities Act or any other applicable securities laws of the United States. The Company does not intend to make any public offering of securities in the United States.

PegBio Co., Ltd.
派格生物醫藥（杭州）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2565)

PLACING OF NEW H SHARES UNDER GENERAL MANDATE

Overall Coordinators and Joint Placing Agents

CITIC SECURITIES　　ABCI 農銀國際

Capital Market Intermediaries and Joint Placing Agents

YELLOW RIVER SECURITIES　　利弗莫尔证券 LIVERMORE HOLDINGS LIMITED

The Board is pleased to announce that on December 12, 2025 (after trading hours), the Company entered into the Placing Agreement with the Joint Placing Agents, pursuant to which the Company has conditionally agreed to place, through the Joint Placing Agents on a best efforts basis, an aggregate of 5,136,000 Placing Shares to not less than six Placees at a price of HK$58.41 per Placing Share to be issued by the Company under the General Mandate upon the terms and subject to the conditions set out in the Placing Agreement.

As at the date of this announcement, the Company has 385,955,532 Shares, comprising 279,164,339 H Shares and 106,791,193 Unlisted Shares in issue. Assuming that there will be no change in the issued share capital of the Company between the date of this announcement and the Closing Date, the total number of 5,136,000 Placing Shares represents: (i) approximately 1.84% of the H Shares in issue and approximately 1.33% of the total Shares in issue as at the date of this announcement; and (ii) approximately 1.81% of the H Shares and approximately 1.31% of the total Shares as enlarged by the allotment and issue of the Placing Shares.

The Placing Price of HK$58.41 per Placing Share represents: (i) a discount of 10% to the closing price of HK$64.90 per H Share as quoted on the Stock Exchange on December 12, 2025 (Hong Kong time), being the date of the Placing Agreement; and (ii) a discount of approximately 7.11% to the average closing price of HK$62.88 per H Share as quoted on the Stock Exchange for the five consecutive trading days immediately prior to the date of the Placing Agreement.

The Placing Shares will be allotted and issued under the General Mandate, and therefore no Shareholders' approval is required for the allotment and issue of the Placing Shares.

An application will be made by the Company to the Listing Committee of the Stock Exchange for the listing of, and permission to deal in, the Placing Shares.

Since completion of the Placing is subject to the satisfaction of the conditions set out in the Placing Agreement, the Placing may or may not proceed. Shareholders and potential investors are advised to exercise caution when dealing in the Shares or other securities of the Company.

The Board is pleased to announce that on December 12, 2025 (after trading hours), the Company entered into the Placing Agreement with the Joint Placing Agents, pursuant to which the Company has conditionally agreed to place, through the Joint Placing Agents on a best efforts basis, an aggregate of 5,136,000 Placing Shares to not less than six Placees at a price of HK$58.41 per Placing Share to be issued by the Company under the General Mandate upon the terms and subject to the conditions set out in the Placing Agreement.

The principal terms of the Placing Agreement are summarized below:

THE PLACING AGREEMENT

Date

December 12, 2025 (after trading hours)

Parties

(i) the Company (as issuer); and

(ii) the Joint Placing Agents (as placing agents)

To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, each of the Joint Placing Agents and its ultimate beneficial owners are Independent Third Parties.

The Placing

The Joint Placing Agents have conditionally and severally (not jointly nor jointly and severally) agreed, as agents of the Company, to procure, on a best effort basis, the placing of 5,136,000 Placing Shares (with total nominal value of RMB5,136,000) at the Placing Price of HK$58.41 per Placing Share.

The Placees

It is expected that the Joint Placing Agents will procure, on a best effort basis, to place the Placing Shares to not less than six Placees who are professional, institutional, or other investors who and whose ultimate beneficial owners are Independent Third Parties. It is expected that none of the Placees will become a substantial shareholder (as defined under the Listing Rules) of the Company as a result of the Placing.

Number of Placing Shares

Under the terms of the Placing Agreement and subject to the conditions of Placing Agreement, the Company will issue 5,136,000 new H Shares with a nominal value of RMB1.00 each in the registered share capital of the Company.

As at the date of this announcement, the Company has 385,955,532 Shares, comprising 279,164,339 H Shares and 106,791,193 Unlisted Shares in issue. Assuming that there will be no change in the issued share capital of the Company between the date of this announcement and the Closing Date, the total number of 5,136,000 Placing Shares represents: (i) approximately 1.84% of the H Shares in issue and approximately 1.33% of the total Shares in issue as at the date of this announcement; and (ii) approximately 1.81% of the H Shares and approximately 1.31% of the total Shares as enlarged by the allotment and issue of the Placing Shares.

The Placing Shares, when issued and fully paid, shall rank pari passu in all respects with the other H Shares then in issue free from all encumbrances, and together with all rights attaching to them as at the date of issue of the Placing Shares, including the right to receive all dividends and/or distributions declared, made or paid at any time after the date of issuance.

Placing Price

The Placing Price of HK$58.41 per Placing Share represents: (i) a discount of 10% to the closing price of HK$64.90 per H Share as quoted on the Stock Exchange on December 12, 2025 (Hong Kong time), being the date of the Placing Agreement; and (ii) a discount of approximately 7.11% to the average closing price of HK$62.88 per H Share as quoted on the Stock Exchange for the five consecutive trading days immediately prior to the date of the Placing Agreement.

The net Placing Price (after deducting related costs and expenses to be borne by the Company) is approximately HK$57.57 per Placing Share. The Placing Price was determined on an arm's length basis between the Company and the Joint Placing Agents, with reference to the market condition and the prevailing market prices of the H Shares. The Directors consider that the Placing Price is fair and reasonable and the Placing is in the interests of the Company and the Shareholders as a whole.

Conditions Precedent and Closing

Completion of the Placing is conditional upon the satisfaction or waiver (as applicable) of, among others, the following conditions:

(A) there shall not have occurred any material breach or any event rendering materially untrue or inaccurate, any of the representations, warranties or undertakings by the Company under the Placing Agreement;

(B) any suspension or limitation of trading in any of the Company's securities by the Stock Exchange (save and except for any trading halt in relation to the Placing);

(C) the Listing Committee of the Stock Exchange granting the listing of, and permission to deal in, the Placing Shares (and such listing and permission not subsequently being revoked prior to the allotment and issuance of Placing Shares);

(D) the representations and warranties made by the Company pursuant to the Placing Agreement being true and accurate and not misleading as of the date of the Placing Agreement and the Closing Date;

(E) the Company having complied with all of the agreements and undertakings and satisfied all of the conditions on its part to be complied with or satisfied with under the Placing Agreement on or before the Closing Date;

(F) the Overall Coordinators having received on the Closing Date the draft of the CSRC Filings and the relevant PRC legal opinion as specified in the Placing Agreement; and

(G) the Placing Agreement not being terminated by the Overall Coordinators.

The Overall Coordinators in their sole discretion may waive any of the conditions (other than condition (C) which may not be waived), in whole or in part and with or without conditions, by notice to the Company.

The Closing is expected to take place on December 22, 2025 but in any event no later than December 31, 2025, or such other date as the Company and the Overall Coordinators may agree in writing.

Lock-up Undertakings by the Company

The Company shall not, without the prior written consent of the Overall Coordinators, (i) effect or arrange or procure placement of, allot or issue or offer to allot or issue or grant any option, right or warrant to subscribe for, or enter into any transaction which is designed to, or might reasonably be expected to, result in any of the aforesaid (whether by actual disposition or effective economic disposition due to cash settlement or otherwise), directly or indirectly, any equity securities of the Company or any securities convertible into, or exercisable, or exchangeable for, equity securities of the Company, or (ii) enter into any swap or similar agreement that transfers, in whole or in part, the economic risk of ownership of such Shares, whether any such transaction described in (i) or (ii) above is to be settled by delivery of Shares or such other securities, in cash or otherwise, or (iii) publicly announce an intention to effect any such transaction, for a period beginning on the date of the Placing Agreement and ending on the date which is 90 days after the Closing Date. The foregoing shall not apply to (i) the issue of the Placing Shares under the

Placing Agreement, (ii) the issue of Shares or securities convertible into or exercisable for Shares pursuant to the conversion or exchange of convertible or exchangeable securities or the exercise of warrants or options (including net exercise) or the settlement of restricted share units (including net settlement), in each case outstanding on the date of the Placing Agreement; (iii) grants of share options, share awards, or other equity awards and the issuance of Shares or securities convertible into or exercisable or exchangeable for Shares (whether upon the exercise of share options or otherwise) to the relevant eligible participants pursuant to the terms of any share scheme of the Company in effect as of the Closing Date.

Application for Listing

An application will be made by the Company to the Listing Committee of the Stock Exchange for the listing of, and permission to deal in, the Placing Shares.

Filing with Regulatory Authorities in the PRC

After the Placing Shares are issued and listed on the Stock Exchange, the Company will file with the regulatory authorities in the PRC in accordance with the relevant applicable laws and regulations, including the CSRC Filings.

Since completion of the Placing is subject to the satisfaction of the conditions set out in the Placing Agreement, the Placing may or may not proceed. Shareholders and potential investors are advised to exercise caution when dealing in the Shares or other securities of the Company.

EFFECT ON THE SHARE CAPITAL OF THE COMPANY AS A RESULT OF THE PLACING

	As at the date of this announcement		Immediately after the completion of the Placing	
	Number of Shares	Approximate Percentage of the total number of Shares in issue[1]	Number of Shares	Approximate Percentage of the total number of Shares in issue
H Shares				
Dr. Michael Min XU[2]	46,599,792	12.07%	46,599,792	11.92%
Ms. Xiaojun WANG[2]	29,175,230	7.56%	29,175,230	7.46%
Dr. Xiangjun ZHOU	6,268,463	1.62%	6,268,463	1.60%
Dr. Yuhong XU	6,810,871	1.76%	6,810,871	1.74%
Placees	0	0.00%	5,136,000	1.31%
Other shareholders	190,309,983	49.31%	190,309,983	48.66%
Sub-total	**279,164,339**	**72.33%**	**284,300,339**	**72.69%**
Unlisted Shares				
Dr. Michael Min XU	40,657,312	10.53%	40,657,312	10.40%
Other shareholders	66,133,881	17.14%	66,133,881	16.91%
Sub-total	**106,791,193**	**27.67%**	**106,791,193**	**27.31%**
Total	**385,955,532**	**100.00%**	**391,091,532**	**100.00%**

Notes:

1. *The calculation is based on the total number of 106,791,193 Unlisted Shares and 279,164,339 H Shares in issue as at the date of this announcement.*

2. *Shanghai Sujie was established in the PRC as a limited partnership, of which Ms. Xiaojun WANG is acting as the sole general partner, and Dr. Michael Min XU owns approximately 93.10% interest as a limited partner at the date of this announcement. As such, Ms. Xiaojun WANG and Dr. Michael Min XU are deemed to be interested in the 29,175,230 H Shares held by Shanghai Sujie under the SFO.*

3. *The above assumes there is no change to the issued share capital of the Company from the date of this announcement up to the Closing Date, save for the allotment and issue of the Placing Shares.*

4. *Certain figures and percentage figures included in the above table have been subject to rounding adjustments.*

REASONS FOR AND BENEFITS OF THE PLACING AND USE OF PROCEEDS

The Directors consider that the Placing represents an opportunity to support the Group's long-term development strategy, raise capital for the Company for future business opportunities as and when they arise, as well as broaden the Shareholder base of the Company. Upon the completion of the Placing, the proceeds raised will further enhance the Group's financial strength, market competitiveness and comprehensive strength, and promote the long-term healthy and sustainable development of the Group.

Assuming that all the Placing Shares are fully placed, the estimated gross proceeds and net proceeds (after deducting related costs and expenses to be borne by the Company) from the Placing will amount to approximately HK$299,993,760 and approximately HK$295,699,826, respectively.

The table below sets out the intended uses of the net proceeds of the Placing:

Expected use of net proceeds		**Approximate percentage of the total net proceeds**	**Allocation of net proceeds** ***(HK$ million)***	**Expected timeline for utilization of the net proceeds**
(I)	Construction of a new-generation intelligent R&D and data platform	40%	118.28	Expected to be fully utilized by the end of 2026
(II)	Repayment of loans and strengthening of the Company's capital structure	28%	82.80	Expected to be fully utilized by the end of 2026
(III)	Ongoing and planned R&D of PB-2301 and PB-2309	12%	35.48	Expected to be fully utilized by the end of 2026
(IV)	Establishment of a HK subsidiary and acceleration of the Groups' overseas presence	10%	29.57	Expected to be fully utilized by the end of 2026

Expected use of net proceeds		Approximate percentage of the total net proceeds	Allocation of net proceeds *(HK$ million)*	Expected timeline for utilization of the net proceeds
(V)	General corporate purposes and working capital	10%	29.57	Expected to be fully utilized by the end of 2026
Total		**100%**	**295.69**	

Note: The expected timeline is based on the best estimation of future market conditions and business operations made by the Company currently and remains subject to change based on future development of market conditions and actual business needs.

The net proceeds from the Placing will be primarily utilized for the following purposes:

(I) Construction of a new-generation intelligent R&D and data platform (Approximately 40% of net proceeds)

The allocated proceeds from the Global Offering for R&D activities is primarily reserved for advancing the established clinical-stage pipeline and traditional-method-based drug discovery. Following the Listing, the Company recognizes the necessity of a strategic investment in an underlying R&D infrastructure in order to consolidate and expand its technological leadership in the chronic disease treatment field. The intended construction of a new-generation intelligent R&D platform aims to systematically enhance R&D efficiency from target discovery to the identification of clinical candidate molecules through the deep integration of computational science and biotechnology, while also providing critical data support for real-world evidence generation and lifecycle management of core products post-launch.

The Company's core product and R&D pipeline are all focused on the complex chronic disease field, where the drug discovery process heavily relies on the integration and analysis of vast, multi-omics biomedical data and real-world clinical data. The limitation of existing traditional platforms, in terms of data processing capacity, throughput, and model iteration speed, have gradually become bottlenecks in the R&D process. Therefore, building an intelligent platform with greater computational power, superior algorithms, and higher data integration is an inevitable strategic choice to accelerate the advancement of the Company's existing pipeline and improve the success rate of future drug candidates.

Below is a further breakdown of the intended use of proceeds allocated for the con construction of a New-Generation Intelligent R&D and Data Platforms:

A. *New-generation integrated drug discovery platform (approximately 18% of the net proceeds)*

Approximately 18 % of the net proceeds from the Placing will be used to investing in high-performance computing clusters, AI-assisted molecular design and optimization software, and automated laboratory information systems. This platform will be directly applied to the Company's in-house R&D projects in core therapeutic areas such as metabolism, including but not limited to T2DM, obesity, and non-alcoholic fatty liver disease. By enabling more precise molecular simulations and virtual screening, the platform aims to shorten lead compound optimization cycles and reduce the cost and time associated with trial-and-error in preclinical R&D.

B. *Unified Chronic Disease Specialized Database and Analysis System (approximately 12% of the net proceeds)*

Approximately 12 % of the net proceeds from the Placing will be used to construct a strategic intelligence hub for integrating internal and external data resources, which is designed to systematically consolidate and mine diverse R&D data both within and outside the Group. The platform will not only aggregate clinical trial results, multi-omics data, and real-world diagnosis and treatment data, but will also incorporate global competitors' target landscape, pipeline progress, clinical trial results, and patent intelligence. It will interface with authoritative disease databases and public multi-omics data resources. By applying AI-driven data mining and comparative analysis technologies, the system can dynamically track and analyze the global R&D dynamics for similar targets, which will be able to serve the following two main purposes: (i) identifying differentiated targets and optimizing molecules for projects in the R&D pipeline, thereby avoiding redundant research and discovering emerging opportunities; and (ii) providing lifecycle management insights for marketed products based on the competitive landscape, enabling timely identification of potential directions for market positioning adjustments and indication expansion. Ultimately, the platform will provide crucial data and decision-making support that extends beyond internal perspectives for setting the Company's overall R&D strategy priorities, making pipeline iteration decisions, and precisely allocating R&D resources.

C. *Digital Patient Management and Research Platform (approximately 10% of the net proceeds)*

Approximately 10% of the net proceeds from the Placing will be used to build an innovative chronic disease management platform designed to enhance patient treatment adherence and quality of life through digital means, forming a closed-loop service system. The platform will develop intelligent self-management tools for patients, including features such as medication reminders, symptom logging, health education, and personalized lifestyle guidance, empowering patients to conduct continuous self-health monitoring and management. By establishing this complete digital health intervention mechanism, the platform aims to optimize long-term treatment outcomes and build a patient support system covering the entire lifecycle for the Company's marketed products, along with a real-world data feedback loop.

(II) Repayment of Loans and Strengthening of the Company's Capital Structure (Approximately 28% of the net proceeds)

To strengthen the Company's capital structure and to reduce financing costs, approximately 28% of the net proceeds from the Placing has been allocated for repayment of the Company's existing bank loans. As of November 30, 2025, the aggregate outstanding principal of the Company's bank loans was approximately RMB89.90 million (equivalent to HK$98.80 million). The Placing plans to allocate no more than HK$82.8 million specifically for settling the principal and interest of existing loans. This arrangement will directly reduce the Company's interest expenses, enhance net profit and significantly improve the debt ratio, thereby optimizing the balance sheet structure and reserving financing capacity for future business development.

(III) Ongoing and planned R&D of PB-2301 and PB-2309 (Approximately 12% of the net proceeds)

Approximately 12% of the net proceeds from the Placing has been allocated for advancing the core development work prior to submitting an investigational new drug (IND) application for the Company's pipeline products PB-2301 and PB-2309, covering the following key aspects: (1) CMC development and manufacturing – for formulation and process development, and the GMP manufacturing of toxicology and clinical batch samples for both products; (2) quality research and stability – for establishing analytical methods and quality control systems, and conducting comprehensive stability studies; and (3) IND submission preparation – for compiling and submitting regulatory-compliant IND application materials.

This investment is intended to efficiently advance both products to the IND stage, thereby accelerating the initiation of clinical trials, enriching the Company's clinical-stage pipeline, and laying a foundation for long-term growth.

(IV) Establishment of a HK subsidiary and acceleration of the Groups' overseas presence (Approximately 10% of the net proceeds)

Since the Listing, while the Company has endeavored to push forward the market launch of its core product, the Company has also achieved significant progress in its negotiations with potential international partners. Opportunities for global business expansion have become more defined and urgent than at the time of the Listing.

To effectively implement this internationalization strategy, approximately 10% of the proceeds from the Placing has been allocated for (i) establishment a Hong Kong subsidiary which will serve as a strategic hub for the Group to manage and expand its global business, and will carry out functions as the Group's overseas financing center, an international strategic cooperation platform and global operation headquarters and (ii) acceleration of the Groups' overseas presence.

The net proceeds from the Global Offering allocated to business development activities and enhancing the Group's overseas presence (approximately RMB2.1 million) were primarily for the use of business development activities such as participation and organization of academic, whereas the current use of proceeds is primarily focused on developing top-level structural capabilities to support the overseas entity operations, address diverse regulatory environments and attract international top talents, which is necessary in order for the Group to respond to the rapidly emerging global opportunities.

Considering that negotiations with multiple international partners have reached a critical stage, as well as the lead time required for the establishment of the entity and commencement of operations, the Company believes the capital investment needs for this structure are urgent at the present stage.

Meanwhile, the Company may from time to time identify potential collaboration partners and investment targets and look for opportunities to accelerate the Group's overseas presence.

(V) General Corporate Purposes and Working Capital (Approximately 10% of the net proceeds)

With the approval and launch of the Company's core products, the business focus has transitioned from the R&D phase to the full-scale commercialization phase, resulting in a significant change in the structure and scale of capital requirements.

To address working capital needs arising from key commercialization tasks such as large-scale production, multi-channel market access, continuous operation and maintenance of the AI-based commercialization system, and strategic inventory reserves, the Company intends to allocate approximately 10% of the net proceeds from the Placing for general corporate purposes and working capital to ensure stable supply, market penetration and operational support following product launch. Such allocation of intended use of proceeds is aligned with the Company's business phase transformation, with an aim to provide the necessary liquidity support for the Company to successfully achieve the commercialization transition.

Based on the above, the Company believes that the Placing will provide it with key strategic resources, enabling it to effectively seize global expansion opportunities arising after product launch, adapt to the rapidly evolving technological paradigm, deploy efficient AI-driven commercialization capabilities, and also lay a solid financial foundation for the upcoming large-scale commercialization phase, thereby ultimately creating long-term value for the shareholders.

In view of the above, the Directors consider that the terms of the Placing Agreement (including but not limited to the Placing Price and the Placing commission payable to the Placing Agents) are fair and reasonable and the Placing is in the interests of the Company and its Shareholders as a whole.

GENERAL MANDATE

By the resolution of the Shareholders passed on February 14, 2024, a General Mandate was granted to the Directors to allot and issue Shares at any time within a period up to the date of the conclusion of the next annual general meeting of the Shareholders to be held after the Listing or the date on which the Shareholders pass a resolution to revoke or change such mandate, whichever is earlier, upon such terms and conditions and for such purposes as the Board in their absolute discretion deem fit, and to make necessary amendments to the Articles of Association, provided that, the number of Shares to be issued shall not exceed 20% of the number of the Shares in issue as at the Listing Date.

Since the grant of the General Mandate and up to the date of this announcement, the Directors have not exercised their power to allot or issue any new Shares pursuant to such General Mandate.

The Placing Shares will be allotted and issued under the General Mandate, and therefore no Shareholders' approval is required for the allotment and issue of the Placing Shares.

EQUITY FUND RAISING ACTIVITIES OF THE COMPANY IN THE PAST 12 MONTHS

The H Shares were listed on the main board of the Stock Exchange on May 27, 2025 with a total of 19,283,500 offer shares issued at an issued price of HK$15.6 per H Share. The net proceeds raised from the Global Offering were approximately HK$231.8 million (equivalent to RMB212.6 million) after the deduction of underwriting fees, and related expenses in connection with the Global Offering.

The net proceeds from the Global Offering will be utilized in accordance with the purposes set out in the Prospectus. There was no change in the intended use of net proceeds as previously disclosed in the Prospectus.

The table below sets out the applications of the net proceeds and actual usage up to November 30, 2025:

Use of proceeds	**Approximate % of total net proceeds** *(%)*	**Planned allocation of net proceeds** *(RMB million)*	**Utilized net Proceeds for the period from Listing to November 30, 2025** *(RMB million)*	**Unutilized net Proceeds (as of November 30, 2025)** *(RMB million)*	**Expected timeline for application of unutilized net proceeds**
Commercialization and indication expansion of our Core Product PB-119	50.2	106.7	0.7	106	Expected to be fully utilized by the end of 2027
Further development of our key product PB-718	34.5	73.3	1.1	72.2	Expected to be fully utilized by the end of 2027
Ongoing and planned research and development of our other pipeline product candidates	5.3	11.3	3.1	8.2	Expected to be fully utilized by the end of 2026
Business development activities and enhancing our overseas presence	1.0	2.1	0.05	2.07	Expected to be fully utilized by the end of 2026

Use of proceeds	Approximate % of total net proceeds *(%)*	Planned allocation of net proceeds *(RMB million)*	Utilized net Proceeds for the period from Listing to November 30, 2025 *(RMB million)*	Unutilized net Proceeds (as of November 30, 2025) *(RMB million)*	Expected timeline for application of unutilized net proceeds
Working capital and other general corporate	9.0	19.2	16.5	2.6	Expected to be fully utilized by the end of 2025
Total	**100**	**212.6**	**21.4**	**191.2**	

Note: The expected timeline is based on the best estimation of future market conditions and business operations made by the Company currently and remains subject to change based on future development of market conditions and actual business needs.

Save as disclosed above, the Company has not conducted any fund raising activities in the 12 months immediately preceding the date of this announcement.

AMENDMENTS TO THE ARTICLES OF ASSOCIATION

Upon completion of the Placing, the registered capital and total number of the Shares of the Company will be changed to RMB391,091,532 and 391,091,532 Shares, respectively. To reflect such changes in the registered capital and total share capital of the Company, corresponding amendments will be made to the Articles of Association (the "**Amendments to the Articles of Association**").

In accordance with the resolution in relation to the General Mandate passed at the annual general meeting of the Company held on February 14, 2024, the Shareholders have authorized the Board to make any amendments to the Articles of Association as it deems necessary. As such, the Amendments to the Articles of Association do not require further Shareholders' approval and will become effective from the date of completion of the Placing.

Details of the Amendments to the Articles of Association will be disclosed by the Company in due course.

INFORMATION ABOUT THE COMPANY

The Company is a biotechnology company focused on the in-house discovery and development of innovative therapies, primarily peptide and small molecule drugs, for chronic diseases with a particular emphasis on metabolic disorders.

DEFINITIONS

In this announcement, the following expressions have the meanings set out below unless the context requires otherwise:

"Board"	the board of Directors
"Business Day"	any day (excluding a Saturday and Sunday) on which banks are generally open for business in Hong Kong during normal working hours
"Capital Market Intermediaries"	ABCI Securities Company Limited, Yellow River Securities Limited and Livermore Holdings Limited, acting as the capital market intermediaries and placing agents of the Placing
"China", or "PRC"	the People's Republic of China which, for the purpose of this announcement, excludes Hong Kong, Macau Special Administrative Region of the People's Republic of China, and China's Taiwan
"Closing"	closing of the Placing in accordance with the Placing Agreement
"Closing Date"	the date on which the closing of the Placing will take place, which is expected to be December 22, 2025, or such other date as the Company and the Overall Coordinators may agree in writing
"Company"	PegBio Co., Ltd. (派格生物醫藥(杭州)股份有限公司) (formerly known as PegBio Co., Ltd. (派格生物醫藥(蘇州)股份有限公司)), a limited liability company incorporated in the PRC on May 13, 2008 and converted into a joint stock company with limited liability on December 30, 2020
"connected person(s)"	has the meaning ascribed thereto in the Listing Rules
"CSRC"	China Securities Regulatory Commission
"CSRC Filings"	the filing report (including any amendments, supplements and/or modifications thereof) in relation to the Placing and any transactions contemplated by the Placing Agreement and any relevant supporting materials (including, but not limited to, the PRC legal opinion to be issued by the counsel for the Company on the PRC laws, where applicable) to the CSRC pursuant to the CSRC Filing Rules
"CSRC Filings Rules"	the Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies (境內企業境外發行證券和上市管理試行辦法) and supporting guidelines issued by the CSRC on 17 February 2023 (as amended, supplemented or otherwise modified from time to time);
"Director(s)"	the director(s) of the Company
"General Mandate"	the general mandate granted to the Board pursuant to a resolution of the Shareholders passed on February 14, 2024

"Global Offering"	the initial public offering of the shares on the terms and subject to the conditions as described in the Prospectus
"Group"	the Company and its subsidiaries
"HK$"	Hong Kong dollars, the lawful currency of Hong Kong
"H Share(s)"	listed ordinary share(s) in the share capital of our Company with a nominal value of RMB1.00 each, which is/are subscribed for and traded in HK dollars and listed on the Stock Exchange
"Independent Third Parties"	person(s) who is(are) third party(ies) independent of the Company and its connected persons (as defined under the Listing Rules)
"Joint Placing Agents"	CLSA Limited, ABCI Capital Limited, ABCI Securities Company Limited, Yellow River Securities Limited, and Livermore Holdings Limited
"Listing"	the listing of the H Shares on the main board of the Stock Exchange
"Listing Date"	May 27, 2025
"Listing Rules"	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended, supplemented or otherwise modified from time to time
"Overall Coordinators"	CLSA Limited and ABCI Capital Limited, acting as the placing agents and overall coordinators of the Placing
"Placee(s)"	any individuals, corporate, institutional or other investor(s) procured by the Joint Placing Agents or its agents to subscribe for any of the Placing Shares pursuant to the Placing Agreement
"Placing"	the placing of 5,136,000 Placing Shares pursuant to the terms of the Placing Agreement
"Placing Agreement"	the conditional placing agreement entered into between the Company and the Joint Placing Agents dated December 12, 2025 in relation to the Placing
"Placing Price"	HK$58.41 per Placing Share
"Placing Shares"	5,136,000 new H Shares to be allotted and issued under the terms and conditions of the Placing Agreement
"Prospectus"	the prospectus of the Company dated May 27, 2025
"RMB"	Renminbi, the lawful currency of the PRC
"SFO"	the Securities and Futures Ordinance (Chapter 571), as amended, supplemented or otherwise modified from time to time

"Shanghai Sujie"	Shanghai Sujie Business Management Consulting Partnership (Limited Partnership) (上海蘇頡企業管理諮詢合夥企業(有限合夥)), a limited partnership established in the PRC on August 28, 2020, the equity incentive platform of our Group of which Ms. Xiaojun WANG, our executive Director and Chief Financial Officer, is the sole general partner
"Share(s)"	ordinary Share(s) of the Company with a nominal value of RMB1.00 each, comprising H Share(s) and Unlisted Share(s)
"Shareholder(s)"	the holder(s) of Shares
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"Unlisted Share(s)"	ordinary share(s) issued by the Company, with a nominal value of RMB1.00 each, which is/are not listed on any stock exchange
"%"	per cent

By order of the Board
PegBio Co., Ltd.
Michael Min XU
Chairman of the Board, Executive Director and General Manager

Hong Kong, December 12, 2025

As of the date of this announcement, the board of directors of the Company comprises: (i) Dr. Michael Min XU and Ms. Xiaojun WANG as executive directors; (ii) Dr. Xiangjun ZHOU, Dr. Yuhong XU, Ms. Ting ZHAI and Mr. Hongkai LI as non-executive directors; and (iii) Dr. Jiancun ZHANG, Dr. Yangyang CHEN and Ms. Xinpeng FAN as independent non-executive directors.